Clinical Trial

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of VG2025 Intravenous Injection in Subjects With Advanced Solid Tumors

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
VG2025 is a Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection. This Phase I study will be conducted in herpes simplex virus (HSV) -seropositive subjects with advanced malignant solid tumors that are refractory to conventional therapies. This is an open label study to determine the safety and tolerability of VG2025, and recommended dose of VG2025 for Phase II trials.
Trial Details
NCT Number NCT07682870
Lead Sponsor Virogin Biotech Ltd.
Conditions Advanced Malignant Solid Tumor
Enrollment 42 participants
Start Date 2026-09-04
Primary Completion 2028-12-02 (estimated)
Study Completion 2029-09-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-06